. 2003 Jun;47(6):1979–1983. doi: 10.1128/AAC.47.6.1979-1983.2003

TABLE 2.

Prevention of S. aureus infection using RIP-coated Dacron grafts in the presence or absence of local antibiotic prophylaxis

Antibiotic(s)	Bacterial concn (log CFU/ml [mean ± SD])^a
Antibiotic(s)	MRSA	MSSA
Control (untreated)	7.73 ± 0.11	7.49 ± 0.07
RIP	4.52 ± 0.09^b^,^c	4.64 ± 0.06^b^,^c
Mupirocin	2.91 ± 0.16^b	2.84 ± 0.17^b
Mupirocin + RIP	<1^b^,^d^,^e	<1^b^,^d^,^e
Rifampin	4.85 ± 0.15^b	4.92 ± 0.14^b
Rifampin + RIP	2.96 ± 0.09^b^,^f	3.57 ± 0.04^b
Quinupristin-Dalfopristin	1.68 ± 0.08^b	1.64 ± 0.19^b
Quinupristin-Dalfopristin + RIP	<1^b^,^e	<1^b^,^e
Levofloxacin	5.9 ± 0.15^b	4.89 ± 0.14^b
Levofloxacin + RIP	4.18 ± 0.19^b^,^g	3.93 ± 0.09^b

n = 15 rats per group.

P < 0.05 versus untreated control group.

P < 0.05 versus mupirocin treatment, and Quinipristin-dalfopristin treatment.

P < 0.05 versus mupirocin treatment.

P < 0.05 versus levofloracin-RIP treatment and rifampin-RIP treatment.

P < 0.05 versus rifampin treatment.

P < 0.05 versus levofloxacin treatment.